North China Pharmaceutical Co (SHSE:600812) Cyclically Adjusted Revenue per Share: ¥6.34 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600812 North China Pharmaceutical Co Ltd SHSE:600812
56 GF Score
Price ¥5.04
GF Value ¥4.85
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is North China Pharmaceutical Co Cyclically Adjusted Revenue per Share?

North China Pharmaceutical Co SHSE:600812 -0.79% 56 Cyclically Adjusted Revenue per Share is ¥6.34 as of Mar. 2026. GuruFocus rates SHSE:600812 with a GF Score™ of 56/100 and a GF Value™ of ¥4.85 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

North China Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥1.275. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥6.34 for the trailing ten years ended in Mar. 2026.

During the past 12 months, North China Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -0.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -5.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of North China Pharmaceutical Co was 18.60% per year. The lowest was -6.90% per year. And the median was 2.05% per year.

As of today (2026-08-16), North China Pharmaceutical Co's current stock price is ¥5.04. North China Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥6.34. North China Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.79.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of North China Pharmaceutical Co was 2.16. The lowest was 0.48. And the median was 0.85.


North China Pharmaceutical Co  (SHSE:600812) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

North China Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.04/6.34
=0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of North China Pharmaceutical Co was 2.16. The lowest was 0.48. And the median was 0.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


North China Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


North China Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for North China Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

North China Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

North China Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.49 7.03 6.53 6.34 6.35

North China Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.35 6.34 6.35 6.35 6.34

SHSE:600812 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, North China Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


North China Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, North China Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where North China Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600812
56GF Score
North China Pharmaceutical Co Ltd SHSE:600812
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

North China Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, North China Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.275/116.3033*116.3033
=1.275

Current CPI (Mar. 2026) = 116.3033.

North China Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.003 101.400 1.150
201609 1.282 102.400 1.456
201612 1.211 102.600 1.373
201703 1.282 103.200 1.445
201706 1.185 103.100 1.337
201709 1.120 104.100 1.251
201712 1.618 104.500 1.801
201803 1.490 105.300 1.646
201806 1.411 104.900 1.564
201809 1.403 106.600 1.531
201812 1.302 106.500 1.422
201903 1.645 107.700 1.776
201906 1.645 107.700 1.776
201909 1.558 109.800 1.650
201912 2.154 111.200 2.253
202003 1.424 112.300 1.475
202006 2.227 110.400 2.346
202009 1.940 111.700 2.020
202012 1.512 111.500 1.577
202103 1.660 112.662 1.714
202106 2.856 111.769 2.972
202109 1.611 112.215 1.670
202112 1.120 113.108 1.152
202203 1.487 114.335 1.513
202206 1.611 114.558 1.636
202209 1.470 115.339 1.482
202212 1.559 115.116 1.575
202303 1.472 115.116 1.487
202306 1.485 114.558 1.508
202309 1.607 115.339 1.620
202312 1.682 114.781 1.704
202403 1.550 115.227 1.564
202406 1.504 114.781 1.524
202409 1.374 115.785 1.380
202412 1.326 114.893 1.342
202503 1.522 115.116 1.538
202506 1.553 114.907 1.572
202509 1.271 115.471 1.280
202512 1.049 115.832 1.053
202603 1.275 116.303 1.275

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥6.34 mean?
North China Pharmaceutical Co (SHSE:600812) has a Cyclically Adjusted Revenue per Share of ¥6.34 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on North China Pharmaceutical Co and its competitors.
Is North China Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
North China Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥6.34. Overall, North China Pharmaceutical Co has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does North China Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
North China Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥6.34 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on North China Pharmaceutical Co and its competitors. North China Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥6.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is North China Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, North China Pharmaceutical Co (SHSE:600812) is currently considered Fairly Valued. The stock's GF Value™ is ¥4.85, compared to a current price of ¥5.04 — trading 3.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥6.34. North China Pharmaceutical Co's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For North China Pharmaceutical Co (SHSE:600812), the current Cyclically Adjusted Revenue per Share is ¥6.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is North China Pharmaceutical Co (SHSE:600812) Overvalued in 2026?

Based on GuruFocus' analysis, North China Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.04 is trading 3.9% above its estimated GF Value™ of ¥4.85. GuruFocus considers North China Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600812:

  • Cyclically Adjusted Revenue per Share: ¥6.34
  • GF Value™: ¥4.85 vs. price of ¥5.04 (3.9% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600812 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


North China Pharmaceutical Co Business Description

Address No. 388 Heping East Road, Shijiazhuang, Hebei, CHN, 050015
North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.
56GF Score

Get the complete analysis for SHSE:600812

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.04
Price
¥4.85
GF Value